Vivace Therapeutics Receives FDA Orphan Drug Designation for VT3989 for Mesothelioma Treatment
Vivace Therapeutics, a company that develops cancer treatments, announced on July 30, 2025, that the U.S. Food and Drug Administration (FDA) has granted its experimental
